ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Abstracts Of “Most Newsworthy” Papers At AACR Meeting

May 27, 1977

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994

Ellence Has Lower Risk Of Heart Damage, Study Finds

August 27, 2004

Sequestration: $1.71 Billion Cut to NIH Budget Will Reduce Number of RPGs

May 17, 2013

FDA To Reorganize Oncology Office Into Four Divisions By Disease Type

August 6, 2010

Physician Indicted for Mail Fraud After allegedly Falsifying Data Of Patients On ECOG, CALGB Trials

March 30, 1984